Actively Recruiting
Evaluation of Oral BRX011 for Safety and Efficacy in Adults with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Led by Biojiva LLC · Updated on 2026-09-23
152
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.
CONDITIONS
Brief Title
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Research Team
J
Joseph Trinh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here